Penumbra, Inc. (NYSE:PEN) insider Arani Bose sold 10,927 shares of the firm’s stock in a transaction that occurred on Tuesday, November 28th. The shares were sold at an average price of $103.96, for a total value of $1,135,970.92. Following the completion of the sale, the insider now owns 639,527 shares in the company, valued at $66,485,226.92. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Arani Bose also recently made the following trade(s):

  • On Wednesday, November 22nd, Arani Bose sold 6,248 shares of Penumbra stock. The shares were sold at an average price of $106.10, for a total value of $662,912.80.
  • On Friday, November 17th, Arani Bose sold 8,133 shares of Penumbra stock. The shares were sold at an average price of $103.50, for a total value of $841,765.50.
  • On Monday, November 20th, Arani Bose sold 47,136 shares of Penumbra stock. The shares were sold at an average price of $105.15, for a total value of $4,956,350.40.
  • On Wednesday, November 15th, Arani Bose sold 16,452 shares of Penumbra stock. The shares were sold at an average price of $105.89, for a total value of $1,742,102.28.

Penumbra, Inc. (NYSE:PEN) opened at $105.90 on Friday. Penumbra, Inc. has a 1 year low of $57.85 and a 1 year high of $116.35.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.07. Penumbra had a negative return on equity of 1.95% and a negative net margin of 2.19%. The company had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $79.17 million. During the same period last year, the firm earned ($0.04) EPS. The firm’s revenue for the quarter was up 24.9% on a year-over-year basis. analysts forecast that Penumbra, Inc. will post -0.15 EPS for the current year.

Several hedge funds have recently modified their holdings of PEN. Eagle Asset Management Inc. increased its position in shares of Penumbra by 168.7% during the 2nd quarter. Eagle Asset Management Inc. now owns 510,918 shares of the company’s stock valued at $44,833,000 after purchasing an additional 320,794 shares during the period. American Century Companies Inc. acquired a new position in shares of Penumbra during the 2nd quarter valued at $26,824,000. Victory Capital Management Inc. acquired a new position in shares of Penumbra during the 3rd quarter valued at $24,232,000. Russell Investments Group Ltd. increased its position in shares of Penumbra by 208.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 160,033 shares of the company’s stock valued at $14,043,000 after purchasing an additional 108,080 shares during the period. Finally, BlackRock Inc. increased its position in shares of Penumbra by 4.7% during the 2nd quarter. BlackRock Inc. now owns 1,815,299 shares of the company’s stock valued at $159,294,000 after purchasing an additional 81,981 shares during the period. Institutional investors own 71.70% of the company’s stock.

PEN has been the topic of several analyst reports. Zacks Investment Research upgraded Penumbra from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Canaccord Genuity raised their target price on Penumbra from $100.00 to $113.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. BMO Capital Markets restated a “buy” rating and issued a $96.00 target price on shares of Penumbra in a research report on Friday, October 13th. Finally, BidaskClub cut Penumbra from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th.

TRADEMARK VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/12/02/penumbra-inc-pen-insider-sells-1135970-92-in-stock.html.

Penumbra Company Profile

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Stock Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related stocks with our FREE daily email newsletter.